Lapatinib Versus Lapatinib Plus Capecitabine As Second-Line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer (Gc): a Randomized Phase Ii Trial of the Arbeitsgemeinschaft Internistische Onkologie (Aio)
نویسندگان
چکیده
منابع مشابه
629plapatinib versus Lapatinib plus Capecitabine as Second-line Treatment in Her2-overexpressing Metastatic Gastro-esophageal Cancer (gc): a Randomized Phase Ii Trial of the Arbeitsgemeinschaft Internistische Onkologie (aio).
S. Lorenzen1, U. Helbig2, J. Riera-Knorrenschild3, G.M. Haag4, M. Pohl5, P. C. Thuss-Patience6, F. Bassermann1, F. Weißinger7, E. Schnoy8, K. Becker9, J. Rüschoff10, A. Eisenmenger11, I. Karapanagiotou-Schenkel11, F. Lordick12 3rd Department of Internal Medicine (hematology/medical Oncology), Klinikum Rechts der Isar, Technische Universität München, Munich, GERMANY 3rd Medical Department, Hemat...
متن کاملLapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
INTRODUCTION Human epidermal growth factor receptor 2 (HER2) amplification is present in a subgroup of gastroo-esophageal cancers (GCs). HER2 inhibition with trastuzumab has shown to improve outcomes in advanced disease. Lapatinib ditosylate (LAP), a dual anti-epidermal growth factor receptor (EGFR) and anti-HER2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved ...
متن کاملLapatinib plus capecitabine for HER2-positive advanced breast cancer.
BACKGROUND Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. In this trial, we compared lapatinib plus capecitabine with capecit...
متن کاملGemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
OBJECTIVE AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was compared with a reverse experimental sequence of capecitabine/erlotinib followed by gemcitabine. METHODS 281 patients with PC were randomly assigned to 1st-line treatment with either gemcitabine plus erlotinib or cap...
متن کاملCorrelation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
BACKGROUND Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. METHODS Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression were quantified in formalin-fixe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2014
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu334.14